Intravenous Immunoglobulin May benefit Some Children With Autism

According to Dr. Frye and colleagues, this is the largest case series examining children with ASD who have been treated with IVIg. The article "Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism" is published in the August issue of Translational Psychiatry.  Using the Cunningham Panel™, the authors identified, for the first time, immune biomarkers that can predict with over 80% accuracy which children with ASD will respond favorably to IVIg treatment. 

Recent studies have shown that some children with autism spectrum disorder have an immune system dysfunction. While the standard of care for ASD is behavioral therapy, individuals with a physiological abnormality, such as an immune dysregulation, may require more comprehensive medical treatment.

Dr. Frye, senior author and primary treating physician, states that "Our study demonstrated that a subset of children with autism spectrum disorder (ASD), particularly those that do not respond to standard interventions, may have autoantibodies that target brain tissue which might qualify them for the diagnosis of autoimmune encephalopathy."

Read the article in its entirety here: http://www.prnewswire.ae/news-releases/intravenous-immunoglobulin-ivig-treatment-may-benefit-some-children-with-autism-spectrum-disorder-693043601.html